Wave Life Sciences Ltd.

Revenue for the second quarter of 2026 was $2.3 million, compared with $8.7 million in the prior-year quarter. R&D expense was $51.3 million versus $43.5 million, G&A expense was $24.8 million versus $18 million, and net loss was $69.4 million versus $50.5 million a year ago. Wave ended the quarter with $490.6 million in cash, cash equivalents and marketable securities, which it expects to fund operations into Q3 2028. Management said it expects milestone payments from GSK in the second half of 2026, but those are not included in the runway.

Paul Bolno framed the quarter as validation of Wave’s RNAi and RNA editing platform, emphasizing multiple positive data sets in the first half of 2026. He said 007, 006 and 008 are the company’s core near-term priorities, with obesity, AATD and PNPLA3 each positioned as differentiated genetics-based programs. His tone was confident and strategic, with repeated references to the company’s proprietary chemistry, durability of silencing/editing, and the possibility of multiple regulatory and commercial paths.

Kyle Moran said second-quarter revenue of $2.3 million came from the GSK collaboration. He attributed the higher R&D spend of $51.3 million to advancing clinical programs, including preparation for the Phase IIa portion of INLIGHT and continued progress on the RNA editing pipeline, while G&A of $24.8 million reflected support for the expanding pipeline and next stages of development. He closed with $490.6 million in cash, cash equivalents and marketable securities and reiterated expected runway into Q3 2028, excluding potential future collaboration milestones.

Analysts focused heavily on 007’s Phase IIa obesity study, asking whether Wave is targeting a 5% placebo-adjusted weight-loss threshold and what biomarker gains would justify expansion into MASH, type 2 diabetes, and lipid indications. Management said the study is designed to capture obesity and cardiometabolic signals through MRI-PDFF, HbA1c, lipids, body composition and muscle-retention measures, and that the key is to see where the strongest differentiated signals emerge. On 006, management clarified that the FDA meeting is the first formal discussion on an accelerated-approval pathway, and on DMD/N531, Paul said partner discussions are ongoing and the company is holding off on an NDA filing until the regulatory path is clearer. Questions also probed whether BMI effects should be expected in diabetics and whether the 007 readout could differ from other incretin-combination programs; Wave said it expects the biology to translate across both diabetic and nondiabetic cohorts, but wants the data to determine the best path forward.